Indian Stock Market Wrap-Up: February 14, 2025
The Indian stock market witnessed a mixed session on February 14, 2025, with benchmark indices closing lower amid broad-based selling. Here are the key highlights and developments from the day
Market Performance
Sensex and Nifty 50: The Sensex closed 199.76 points (0.26%) lower at 75,939.21, while the Nifty 50 depreciated 102.15 points (0.44%) to 22,929.25 .
Currency Markets: The Indian rupee appreciated by 12 paise to close at 86.81 against the US dollar. Factors such as FIIs selling equities, the US delaying tariffs, and global uncertainties impacted currency markets .
Corporate Earnings and Announcements
Manappuram Finance and IIFL Finance: Shares of NBFCs Manappuram Finance and IIFL Finance closed 6% lower following weak Q3 results that missed street estimates. Manappuram Finance’s consolidated net profit declined to ₹278.46 crore for December 2024, compared to ₹575.31 crore in the corresponding quarter of the previous year .
Hinduja Global Solutions: The company recorded a net loss of ₹8.59 crore for the quarter ended December 2024, as against a profit of ₹8.18 crore in the corresponding quarter of the previous year .
Bajaj Consumer Care: The company reported a consolidated net profit of ₹25.31 crore for the quarter ended December 2024, compared to ₹36.34 crore in the corresponding quarter of the previous year .
GlaxoSmithKline Pharmaceuticals: Shares gained 1.41% on the NSE to ₹2,027.05. The company recorded a consolidated net profit of ₹229.88 crore for the quarter ended December 2024, compared to ₹45.72 crore in the corresponding quarter of the previous year .
Corporate Developments
Fortis Healthcare: The company’s subsidiary, Fortis Hospotel, signed definitive agreements for the acquisition of the entire business operations of Shrimann Superspecialty Hospital, located in Jalandhar .
Akums Drugs and Pharmaceuticals: The company was awarded a patent for Benzalkonium Chloride-Free Brinzolamide Ophthalmic Formulation, designed for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension .
Vodafone Idea: The company reiterated its capex guidance of ₹10,000 crore for the Financial Year 2024-25, with approximately ₹5,300 crore already spent till December 31, 2024. Shares traded at ₹8.16 on the NSE, down 5.56% .
Sectoral and Stock-Specific Movements
Top Losers: Oberoi Realty (-4.62%), Godrej Properties (-4.33%), Raymond (-3.69%), and DLF (-2.62%) were among the top losers in the Nifty Realty stocks .
Gainers: GlaxoSmithKline Pharmaceuticals shares gained 1.41% on the NSE to ₹2,027.05 .
Market Analysis
The decline in the benchmark indices can be attributed to broad-based selling across sectors, with mid and small-cap segments being hit the hardest. Concerns over global uncertainties, such as the US delaying tariffs and the ongoing geopolitical tensions, have contributed to the cautious sentiment among investors. Additionally, weak corporate earnings from some key companies have added to the market’s woes.
However, defensive stocks such as healthcare and pharmaceuticals have shown resilience, with companies like GlaxoSmithKline Pharmaceuticals registering gains. This indicates that investors are seeking safe-haven assets amid the market volatility.
Conclusion
The Indian stock market faced headwinds on February 14, 2025, with benchmark indices closing lower due to a combination of weak corporate earnings, global uncertainties, and broad-based selling. Investors are advised to monitor the market closely and consider their risk appetite before making investment decisions. As the week comes to a close, the focus will likely shift to upcoming corporate earnings and global economic indicators, which could provide further direction to the market.
Note: The information provided is based on the search results and is intended for informational purposes only. It does not constitute investment advice. Always consult with a financial advisor before making investment decisions.









